Skip To Main Content
Barbara Di Camillo on Muck Rack

Barbara Di Camillo

As seen in: Nature, PLOS, BMJ Open Diabetes Research & Care, Frontiers, MDPI, Diabetes Research and Clinical Practice
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A digital twin should make a risky claim

|
By Manlio De Domenico, Valeria d’Andrea, Marco Grassia, Giuseppe Mangioni, Barbara Di Camillo
| Nature Verified
As the term ‘digital twin’ spreads across science and technology, it risks losing scientific meaning. Such a twin should not denote just a digital replica, but a computational model that can be updated, tested against intervention and shown to fail.
Open in Who Shared Issue with article?

The BRAINTEASER Datasets: Clinical, Wearable and Environmental Data for ALS & MS Progression Modeling - Scientific Data

|
By Guglielmo Faggioli, Laura Menotti, Stefano Marchesin, Lara Ahmad, Anca Loredana Alungulese, Giovanni Birolo, Pietro Bosoni, Paola Cavalla, Mamede De Carvalho, Sergio Martinez, Sergio Martínez, Marta Gromicho, Enrico Longato, Sara Madeira, Umberto Manera, Erica Tavazzi, Vladimir Urošević, Barbara Di Camillo, Maria Fernanda Cabrera-Umpiérrez
| Nature Verified
Abstract Amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) are debilitating diseases with unpredictable progression. Artificial Intelligence-based tools for modelling disease progression could significantly improve the quality of life for patients and caregivers while supporting clinicians in delivering more personalized and timely care. However, the limited availability of data hinders the development, testing, and reproducibility of such predictive tools.
Open in Who Shared Issue with article?

Bone Marrow CD34+/lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects

|
By Alessandra Trojani, Ester Pungolino, Barbara Di Camillo, Luca Emanuele Bossi
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?
See all 11 articles